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Despite improved vaccination rates against hepatitis B, there remain critical 
barriers to addressing gaps in vaccination coverage. The need of an effective supply 
chain, vaccine waste management, trained healthcare providers and cost are all issues that 
impede mass vaccination campaigns around the world. Microneedle patches have been 
proposed as an alternative mode of vaccination. Microneedle patches consist of micron-
scale projections that are capable of disrupting the stratum corneum by creating holes in 
the skin to deliver therapeutic agents.  Small and lightweight, microneedle patches are a 
promising alternative to the bulky multi-dose vials and syringes currently used in mass 
vaccination campaigns. Furthermore, the high density of antigen presenting cells in the 
the skin make transcutaneous immunization via microneedles advantageous, as they 
target vaccine cargo to the topmost layer of the skin.  
The key goal of this project was to develop a microneedle patch for hepatitis B 
vaccination that is simple to administer and of comparable immunogenicity to 
conventional intramuscular vaccination. Trehalose was used as a stabilizing excipient for 
both coated metal and dissolvable microneedles. Moreover, patches were used in vivo to 
compare the elicited immune response in both mice and rhesus macaques. Additionally, 
the mechanical properties of our microneedle patch were evaluated via both theoretical 
and experimental approaches to predict failure force.  This work shows that microneedle 
patches can successfully encapsulate and deliver hepatitis B antigen to generate a strong 
and sustained immune response in multiple animal models.
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CHAPTER 1. INTRODUCTION 
1.1   Motivation  
Hepatitis B is a viral infection that affects the liver, with the potential to progress to 
chronic disease and cirrhosis. Despite vaccines being available for over three decades, 
global prevalence of chronic carriers is still as high as 20 %.1 Currently, hepatitis B 
vaccination first occurs at birth (as recommended by the CDC), and coverage for infants 
worldwide is at 83%2 - up from 75% in 2010.3 In general, the main hindrances to 
vaccination campaigns are cold chain requirements, training of health professionals and 
complicated logistics stemming from bulky shipments of multi-dose glass vials and 
syringes.4 Limited financial resources or personal preference may also be a driver of 
home births worldwide, resulting in a missed opportunity for infant vaccination.5  While 
hepatitis B vaccine retains significant activity at controlled exposures to heat6, the 
possibility of a dry, temperature stable, and easy to administer vaccine could be the key 
to improving vaccination efforts. Furthermore, because many mothers worldwide don’t 
give birth in a health facility, an easily portable delivery method is essential to improve 
compliance with dosing regimens that require the first dose to occur at birth and typically 
administered by minimally trained birth attendants.4,7  
1.1.1   Hepatitis B (disease) 
Hepatitis B Virus (HBV) is a viral infection that targets the liver. A major global 
health issue, HBV is most prevalent in Southeast Asia, the Middle East and sub-Saharan 
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Africa63 (Figure 1). Approximately 4.5 million new HBV infections occur worldwide 
each year.8 
 
Figure 1:Prevalence of chronic hepatitis B infection. Areas with > 8% are shown in 
red and considered to be areas of high HBV prevalence. Reproduced from Lebre, 
et.al.9  
In the US alone, approximately 0.7-1.4 million people have chronic hepatitis B 
infection.10 With 40% of people globally in contact with or identified as carriers 9, HBV 
can spread by percutaneous or mucosal exposure to infectious blood or body fluids such 
as saliva, vaginal or seminal fluids. 3 
HBV can cause both acute and chronic (> 6 months) infections – symptoms 
include fever, fatigue, jaundice, abdominal pain and vomiting. Between one-third and 
one-quarter of persons infected chronically with HBV are expected to develop long-term 
consequences, such as cirrhosis and liver cancer.9  
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1.1.2   Coverage of Vaccination 
The vaccination schedule for hepatitis B consists of a three-dose series. In the US, 
reported hepatitis B vaccination coverage (≥3 doses) varies widely by age group – 32.2% 
among adults aged 19-49 years, and 15.7% among adults aged ≥50 years.11 Globally, 
HBV vaccination coverage is much lower.65  
1.2   Objectives 
The objectives of this study are to fabricate a dissolvable microneedle patch for 
hepatitis B vaccination.  The mechanical properties of these patches were evaluated using 
theoretical and experimental approaches. Immunogenicity of these patches was evaluated 











CHAPTER 2.   BACKGROUND 
2.1   Hepatitis B Vaccine 
Hepatitis B vaccine consists of a liquid suspension of purified hepatitis B surface 
antigen (HBsAg), adsorbed onto some type of aluminum salt. The first vaccines 
developed were plasma-derived and made commercially available in 1982.12 Currently, 
both plasma-derived and recombinant protein vaccines are on the market, with the latter 
being most prevalent. Most licensed recombinant hepatitis B vaccines are a 226 amino 
acid product of the S gene of HBV 13,62 – the determinant primarily responsible for 
immune response is exposed on the particle surface, same as is the case for the natural 
HBsAg particle. The only significant difference is the naturally occurring glycosylation 
in the natural HBsAg particle.3 
2.1.1   Vaccine Structure  
The HBV virus contains surface proteins (denominated small [S], medium [M] and Large 
[L]), which are produced in excess amounts during infection and also circulate in the 
blood as 22-nm spherical and tubular particles.14 In recombinant vaccines, usually the 
sole protein present is the S protein, which accounts for 60% of natural HBsAg particle 
mass.15  S proteins appear as spike-like protrusions at the particle surface. The “a” 
determinant on top of the S protein has been demonstrated to contain at least three 




2.1.2   Vaccine Stability 
The recommended storage temperature for hepatitis B vaccine is between 2º and 
8º C.64 The vaccine is generally stable for 3 to 4 years from the date of manufacture if 
stored in this temperature range.17 However, the stability of hepatitis B vaccines from 
different manufacturers can vary considerably.18 Most hepatitis B vaccines are relatively 
heat stable and have only a small loss of potency when exposed to heat. Previous work 
has shown that current commercial formulations can still elicit protective titers after 1 
week at 45oC,  or up to several weeks at 40oC.18   
Given the logistical issues that frequently plague immunization efforts world-
wide, many have sought to explore transport-friendly alternatives to liquid formulations. 
Spray-freeze drying is one approach used by some to eliminate cold chain dependence. 
Tonnis, et. al. showed that spray-freeze dried HBsAg in combination with sugars like 
inulin or dextran and trehalose resulted in improved stability and higher IgG immune 
responses for intramuscular administration in comparison to liquid HBsAg.19 The powder 
formulations in this study retained 90% of their immunogenicity after 3 months at 60oC. 
The use of sugars has been long known to lend a stabilizing effect when used as an 
excipient within a vaccine solution, for both liquid and solid formulations.7,20  
2.2   Microneedle Patches 
2.2.1   Microneedle Patch Technology 
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One challenge for intradermal delivery is the need to increase the amount of 
biologicals that can be delivered via the skin. Microneedle patches consist of an array of 
tapered projections which can be applied to the skin to pierce the stratum corneum, and 
therefore address this challenge by coupling physical disruption with the simultaneous 
delivery of a drug cargo into the skin. Microneedles can be classified per the following 
categories: solid, coated, hollow and dissolving (Figure 2: ). Solid, coated and hollow 
microneedles are typically made out of materials like silicon, ceramic and metal21 
whereas dissolvable microneedles rely on a water-soluble matrix that typically 
encapsulates the drug cargo of choice. The training required for application of a 
microneedle patch is minimal in comparison to other methods, and application is 
generally considered to be painless.22 
 
Figure 2: Types of microneedle patches. Adapted from Kim, et.al 23 
Solid microneedles create holes in the skin after which a drug will diffuse from a 
reservoir into the channels created within the epidermis. This “poke and patch” approach 
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has been used for varied applications24, but is often limited by the same supply chain 
requirements that hinder traditional immunization procedures. Similar to hypodermic 
injection, hollow microneedles rely on a lumen through which a drug solution will flow 
into the skin. Drug reservoirs can be pressurized to modulate flow rate and subsequently 
the delivery profile of the drug of interest.23  Both solid and hollow microneedles can 
provide an easier way to transition existing drug formulations into the microneedle 
delivery space, though as mentioned earlier, they pose many of the drug stability and 
logistical issues associated with traditional IM immunization. 
Coated microneedles combine physical disruption of the skin while carrying the 
drug cargo in the form of a coating on its surface. This involves creating a formulation 
suitable for coating that can maintain therapeutic activity throughout the coating process 
and subsequent dissolution into skin. While limited in the amount of drug that can be 
applied onto the microneedle array, this approach presents the advantage of easing supply 
chain constraints, by bypassing the need for cold storage temperatures and the handling 
of liquid vaccines.   
Microneedles can also be made in such a way that they encapsulate heat-sensitive 
proteins while being rigid enough to pierce skin. This is the case for dissolvable 
microneedles, which incorporate the drug of interest within their microneedle matrix, as 
well as other water-soluble materials that provide sufficient mechanical strength to pierce 
skin and dissolve within minutes to deliver a drug cargo. The use of sugar-based 
excipients can protect heat-sensitive proteins during the casting process, and because 
microneedles can be fabricated at room temperature with no harsh solvents, drug activity 
can be maintained.25 Furthermore, dissolvable microneedles leave no biohazardous 
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sharps waste, can be manufactured at low cost, and their thermostability poses an 
additional advantage for vaccination campaigns. 
2.2.2   Vaccination with Microneedle Patches 
The epidermis and dermis possess immunocompetent cells such as Langerhans 
and dermal dendritic cells which assist in adaptive immunity (Figure 3). By incorporating 
a vaccine within the constitutive microneedle matrix or onto the microneedle surface, the 
vaccine can be brought into contact with these antigen presenting cells (APCs)26 to elicit 
an immune response. Since a microneedle’s dimensions are small, there is less risk of 
Figure 3: Antigen presenting cells within layers of skin. Stratum corneum is 10-
20 µm thick. Epidermis and dermis thickness are around 100 µm and 0.3-4 mm, 
respectively. Adapted from Engelke, et. al. 26 
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error for targeting vaccination in the skin in comparison to the Mantoux technique, where 
a 26 or 27 gauge needle is inserted at an angle into the skin.27 This technique is 
particularly challenging to administer consistently. Furthermore, the high density of 
APCs within the skin lends microneedles the potential of generating a strong immune 
response at lower doses than traditional vaccination regimens.28   
In recent years, numerous studies have been published on the use of microneedle 
patches as a vaccination strategy. Typical administration can take between a few minutes 
to a few hours, depending on the type of microneedle and formulation.29–31 In vivo 
studies have demonstrated the efficacy of hollow microneedles for dermal administration 
of inactivated poliovirus vaccine32 in rats. Other examples of intradermal vaccination via 
hollow microneedles is the FDA-approved flu vaccine developed by Sanofi33, as well as 
temperature-stable, dissolvable microneedle patches have been developed for live, 
inactivated, subunit and DNA vaccines such as those for measles34 , influenza23 and 
rabies.35,36 Notably, dissolving microneedle patches containing influenza vaccine with 
calcium heptagluconate and arginine as excipients were shown to retain vaccine stability 
for up to 24 months at room temperature.37 
2.2.3   Potential Impact of Microneedle Patch Vaccination on Public Health 
In 2005, the CDC submitted recommendations to increase vaccination coverage 
by implementing a birth dose of hepatitis B vaccine in medically stable infants.38 Because 
many births worldwide occur away from health facilities and medically trained 
employees, this represents a significant gap in coverage not easily addressed by current 
methods. In 2011, it was found that 37.3-89.9% of the poorest women in developing 
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countries give birth in a home setting.5 Furthermore, in cases of births given by chronic 
HBV carriers – estimated to be around 25,000 per year in the US39-  perinatal HBV 
transmission can be prevented if vaccination occurs within the first 12 hours of an 
infant’s life. Thanks in part to its size and simplicity, a microneedle patch could address 
this need for immediacy and accessibility. Other obstacles for improving vaccination  
coverage include: the need for effective supply chain, vaccine wastage from multi-dose 
vials, need for healthcare provider training, cost and the risk of needle re-use.4 The 
introduction of microneedle patches as an alternative mode of immunization would 
potentially bypass most if not all of these issues.  
Skin vaccination has been shown to produce similar or higher immune responses 
compared to intramuscular injection, with dose-sparing effects presented in some 
cases.40–42 Given that 10% of the general population shows poor immunological response 
to HBV vaccination 43,44, transdermal delivery poses as a potential advantage to patients 
with impaired immune response. Dose sparing has also been observed in some 
microneedle patch applications, which could help maximize coverage under strained 
manufacturing. 
In many cases, the cost of transport and other logistics can double or triple the 
cost of vaccine administration.4 Many academic and commercial ventures are interested 
in transdermal vaccine dosage forms that allow for transport and storage at room 
temperature in a dry state. The incorporation of excipients like sugars allow for hydrogen 
bond formation that is believed to stabilize vaccines by replacing the protein-solvent 
interactions in its liquid state.7 
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The simplicity and minimal risks of microneedle patch application means that the 
dose is already contained and no additional intervention with the antigenic material is 
required. The ability to reconstitute and administer at the same time can minimize 
reconstitution errors, as well as the training needed to safely administer vaccine. 
Dissolvable microneedles eliminate concern over sharps collection and needle-stick 
injuries, eliminating unsafe injection practices that put both health workers and patients at 
risk. Finally, in the case of countries were patient compliance is an issue, it has been 
shown that offering a microneedle patch as an alternative could increase intent to 
vaccinate by 17%.22  
2.3    Transcutaneous Immunization Against Hepatitis B 
Though different from microneedles, liquid HBsAg has already been successfully 
administered intradermally via the use of disposable syringe jet injectors (DSJI) for 
dermal vaccination in the minipig model.45 Several initial studies for transcutaneous 
immunization via microneedles against HBV have focused on leveraging the “poke and 
coat” approach. In this case, metal microneedles are used as a pretreatment, followed by 
the topical application of a vaccine-containing solution. One study using this approach 
developed elastic HBsAg-associated vesicles which were applied following microneedle 
pretreatment, and successfully elicited antibody responses in mice.46 Using a similar 
approach, Guo et. al incorporated HBsAg into carbomer-based hydrogels which were 
applied to mice after pretreatment with solid silicon microneedles.47 Similarly, scraping 
the skin with blunt microneedles has also been used as a technique to deliver DNA 
vaccine against HBV.48  
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More recently there has been interest in developing solid vaccine formulations for 
HBsAg. Coated metal microneedles have been used to deliver bulk HBsAg intradermally 
by incorporating polydi(carboxylatophenoxy)phosphazene as both an excipient and  
immuno-adjuvant.49 In 2015, cationic liposomes encapsulating HBV DNA vaccine were 
delivered via dissolving microneedles in mice.50  Until now, there has not been any work 
incorporating the recombinant HbsAg particles within a completely dissolvable 
microneedle matrix.    
2.4   Mechanical Testing of Microneedles 
In order to ensure efficient drug delivery, microneedles must be able to deliver 
vaccine into the target tissue without mechanical failure. Reliable and reproducible 
insertion depends on microneedles being able to sustain the loads involved during 
administration. In order to understand the loading limits of microneedles, previous 
studies have evaluated the mechanical behavior of microneedles in relation to beam 
failure theory.51 Microneedles are thus treated as columns which can fail in two different 
ways: crushing and buckling. A column with a cross sectional dimension in the vicinity 
of its length (short column), is more likely to be crushed, whereas columns with higher 
aspect ratios fail by buckling. 
2.4.1   Buckling Failure 
Buckling occurs when elastic or inelastic stability of the structure causes the 
structure to fail sideways. Modeling buckling has been treated as an eigenvalue problem, 
where the solution calculation yields a multiplying factor which can be used to scale the 
force applied to that which would be necessary for buckling failure to occur. Many 
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analytical solutions exist in the literature 52,53 for different common structural 
configurations. 
In the case of elastic instability, the Euler equation provides a prediction of the critical 
load required for buckling: 
                                                    𝑷𝒄𝒓 =
𝝅𝟐𝑬𝑰
𝑳𝒆𝟐
                                                           (1) 
Le refers to the effective length (Le=KL) where K is a factor that depends on how 
the microneedle ends are restrained and L is the actual length of the column.51 The K 
values are 1.0, 0.7 and 0.5 for pinned-pinned, pinned-fixed and fixed-fixed columns 
respectively. E represents the tensile or Young’s modulus and I is the moment of inertia 
as calculated below: 
𝐼 =
𝜋𝐷.
64 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2) 
Where D is the equivalent diameter as calculated by Park et. Al48: 
𝐷56 = 	  𝐷789 +
𝐷;<=5 −	  𝐷789
3 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3) 
2.4.2   Insertion Forces  
The forces a microneedle is subjected to during insertion into skin will vary 
according to substrate, application method and microneedle geometry. Currently, most 
microneedle patches used for research are applied manually, but most patches under 
commercial development use of force-driven applicators. These may apply an axial force 
to the microneedle patch that is significantly higher than the minimum insertion force in 
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order to maximize insertion and minimize errors. Representative forces for current 
applicators vary from 3–22 N for patches containing hundreds of sharp-tipped 
microneedles 54, whereas insertion of blunt-tipped, hollow microneedles required 0.1-3 N 
per microneedle.55 Consequently, microneedles must be tough enough to withstand a 
variety of forces.  
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CHAPTER 3.   METHODS 
3.1   HBsAg Quantification and Antibody Titer Measurements 
HBsAg quantification and antibody titers of rhesus macaque serum samples were 
measured using the Vitros Immunodiagnostic System (Ortho Clinical Diagnostics, 
Raritan, NJ) and were carried out at the Centers for Disease Control and Prevention 
(CDC). An immunometric immunoassay technique is used, where HBsAg in the sample 
reacts with mouse monoclonal anti-HBs coated onto wells and with a horseradish 
peroxidase-labelled mouse monoclonal anti-HBs in the conjugate. Bound conjugate is 
measured by a luminescent reaction. Mice serum samples were analysed with a 
commercial anti-HBs ELISA kit (Bio-Rad, Hercules, CA).  
3.2   Concentration of Hepatitis B Vaccine 
Concentrated bulk solution of HBsAg was generously provided by the Serum 
Institute of India (Pune, India). Starting antigen concentration was 2.38 mg/mL. This bulk 
vaccine was concentrated using Vivaspin 20 centrifuge spin filters with a 10 kDa 
molecular weight cutoff (GE Life Sciences, Pittsburgh, PA) by centrifugation at 700 g for 
2 min. Vaccine bulk was concentrated 4-fold and 5.4-fold for the dissolvable and the 
metal microneedles, respectively.  HBsAg concentration was measured via the Vitros 




3.3   Microneedle Fabrication 
3.3.1   Coated Microneedle Patches 
In plane rows of laser-cut stainless-steel microneedle arrays were coated using an 
in-house dip-coating device. The microneedle arrays were fabricated by Tech Etch 
(Plymouth, MA). Each array consisted of 5 microneedles measuring 750 µm in length 
and 170 µm by 50 µm in base cross-sectional area, and arranged in a linear array with 1.6  
mm microneedle tip-to-tip spacing. Two linear micro-positioners allowed for alignment 
and dipping of individual microneedles into a micro-pipette tip containing a coating 
solution. Coating solution consisted of concentrated vaccine mixed 1:1 with a solution of 
2% w/v carboxymethylcellulose (CMC, Sigma–Aldrich, St. Louis, MO) and 20% w/v 
trehalose (Sigma–Aldrich). This device design allowed for coating of only the 
microneedle shaft, thereby avoiding contamination of the array base. Immunoassay 
analysis showed that 1.3 ± 0.1 µg of HbsAg was coated onto coated microneedle patches 
for our mice study. 




Figure 4: Close-up of coated microneedle patch. Scale bar is 500 µm. Inset: Coated 
microneedle patch containing 5 microneedles. (Scale bar: 1mm) 
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3.3.2   Dissolvable Microneedle Patches 
Microneedle patches were fabricated as described previously34,56. In this study, the 
concentrated hepatitis B vaccine stock was mixed into a casting solution at a 60:40 ratio 
with a solution containing 25% w/v trehalose and 2.5% w/v CMC. For our initial mice 
study, unmodified bulk HBsAg (2.38 mg/mL) was used instead of the concentrated 
HBsAg solution. Molds used to fabricate microneedle patches consisted of a 10 x 10 
array of conical cavities in the shape of microneedles, and 35 µL of the vaccine/casting 
solution was applied to each mold. After an hour at room temperature (20 – 25 °C) and 
humidity (20 – 50% rh), a second casting was applied to form a patch backing. This 
solution consisted of sucrose (Sigma–Aldrich) and poly-vinyl alcohol (Acros Organics, 
New Jersey USA) dissolved in deionized water to a final concentration of 0.53 mg/mL of 
each solute at 25°C for 1 h. Vacuum was applied to the mold at room temperature for 3 h. 
After that, molds were allowed to further dry in a desiccator at room temperature for 2 
days. Patches prepared for mechanical testing experiments did not contain HBsAg, and 
phosphate-buffered saline (PBS) was used in lieu of vaccine solution. 
Patches were removed from the mold by applying a polymethylmethacrylate 
(McMaster-Carr, Atlanta, GA) disk covered with double-sided tape (MacTac, Stow, OH) 
to the back of the mold and slowly pulling the patch away from the mold. Upon removal 
from their molds, patches were stored inside a sealed pouch with desiccant (Drierite, 
Xenia, OH) at 4°C for less than 24 h until use. To avoid damaging the microneedles 
through condensation of atmospheric water, pouches were allowed to return to room 
temperature prior to patch removal and application. 
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Immunoassay analysis showed that 0.9 ± 0.3 µg and 12.8 ± 4.0 µg of HBsAg was 
encapsulated in each dissolvable microneedle patch for our mice and macaque study, 
respectively.  
 
3.4   Mechanical Characterization 
3.4.1   Force-Displacement 
Microneedle patches were kept inside sealed pouches with desiccant until testing. 
Failure forces of 10 x 10 microneedle patches under an axial load were measured 
utilizing a digital force gauge (MARK-10 Series 5, Copiague, NY).  Force-displacement 
curves were generated by measuring both force and displacement as the test station’s 
moving crosshead pressed against the microneedle array at a rate of 1.0 mm/min. Upon 
reaching a specific load, the crosshead was immediately lifted. Microneedle patches were 
Figure 5: Dissolving HBsAg microneedle patches. Left: Picture of a 10 x 10 
dissolvable microneedle patch. Scale bar is 1mm. On right: Magnified view of 
conical microneedles.  Scale bar on right is 500µm. 
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then stored inside their original pouches with desiccant – though not sealed – for at least 
24 hours before subsequent insertion into skin. 
3.4.2   Microneedle Insertion 
Sections of frozen porcine skin stored in resealable plastic bags were thawed by 
placing in water (while still inside bag) and then placed on absorbent pads to dry under 
air. A Kimwipe (ThermoFisher, Waltham, MA) was placed on top of the skin section to 
determine if the skin surface was dry. Skin was used within 20 minutes of removal from 
the plastic bag, and only if the Kimwipe indicated a dry skin surface. Microneedle 
patches previously subjected to a specific force load were applied to the skin held under 
tension while applying a force of approximately 7 N and held for 30 seconds. After 20 
minutes, the MN patch was removed and gentian violet dye (HUMCO, Texarkana, TX) 
was applied to the skin to stain puncture spots. The skin was imaged using an Olympus 
SZX16 microscope (Tokyo, Japan) to determine insertion efficiency.  
3.5   Mice Study 
The immunogenicity of hepatitis B vaccine patches was tested in female, 11 week 
old BALB/c mice. They were divided into five groups of 8 animals each. Groups were 
labeled in the following manner: (1) Intramuscular Bulk Vaccine, (2) Reconstituted 
Dissolvable Microneedle Patch, (3) Reconstituted Coated Microneedle Patch, (4) 
Dissolvable Microneedle Patch (dMNP) and (5) Coated Microneedle Patch (cMNP). The 
mice were allowed at least 2 weeks to acclimate before beginning the study. Animals 
were anesthetized using isoflurane during vaccination and blood collection. For animals 
receiving MN patch administration, their backs were shaved using electric shears 
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followed by application of a depilatory cream (Nair, Princeton, NJ) 1 day before 
vaccination. All animals received two vaccine doses (by the same method of delivery) 
separated by three weeks.  
 For intramuscular injection in group 1, stock vaccine was diluted using sterile 
PBS to administer a dose of 2.5 µg HBsAg contained within 25 µL. This solution was 
injected intramuscularly using a 29 gauge hypodermic needle on the animal’s hind leg. 
For group 2, 10 dMNPs (each containing 0.9 ± 0.3 µg HBsAg) were dissolved into 270 
µL of PBS, of which 25 µL containing a dose of 0.8 ± 0.1 µg HBsAg was injected. For 
group 3, 20 cMNPs (each containing 1.3 ± 0.1 µg  HBsAg) were reconstituted in 300 µL 
of PBS, of which 25 µL containing a dose of 2.2 ± 0.04 µg HBsAg was injected. For 
group 4, two dMNPs were applied sequentially to the hairless skin section and left on the 
animal for 10 min per patch to deliver 0.9 ± 0.2 µg HBsAg (based on an expected 
delivery efficiency of 50%).57 For group 5, three cMNPs were applied sequentially to the 
hairless skin section and left on the animal for 10 min per patch to deliver 1.3 ± 0.1 µg 
HBsAg (based on an expected delivery efficiency of 50%). The variability in HBsAg 
dosing levels between groups was due to initial difficulties with analytical methods.  
Visual evidence of skin punctures by MNPs was noticeable (to a trained eye) 
immediately after administration; no bleeding was observed. On some animals, small 
scabs developed from depilatory cream residue left on the skin in initial studies. Care was 
taken to avoid leaving residue during subsequent hair removal. Subsequent patch 
application occurred on intact skin, avoiding the scab area.  Mice were re-shaved and 
depilated prior to the second administration, because fur grew back to normal during the 
3 weeks between first and second administration. Blood was collected on weeks 2, 4, 5 
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and 8 to measure antibody titers (i.e., anti-hepatitis B surface antigen (HBs) titer as 
determined by Spradling, et.al performed at CDC Reference Laboratory).58,59 After week 
8, the animals were sacrificed by isoflurane euthanasia. The protocol for these 
experiments was approved by the Institutional Animal Care and Use Committee 
(IACUC) at Georgia Tech. 
3.6   Macaque Study 
The immunogenicity of the hepatitis B vaccine MNPs was tested in rhesus 
macaques. Animals were divided into three groups of 4 monkeys each. Group I was 
vaccinated intramuscularly with 10 µg unformulated stock vaccine (no adjuvant) and 
Group II was similarly injected with 10 µg of a commercial hepatitis B vaccine 
formulation containing alum adjuvant (Serum Institute of India). Group III received 
hepatitis B vaccination via application of three dMNPs (each containing 12.8 ± 4.0 µg 
HBsAg) that administered 24 ± 8 µg (based on a 63% delivery efficiency; see below), 
respectively. 
Animals were anesthetized via ketamine injection during vaccination and collection 
of blood. For animals receiving microneedle patch administration, their backs were 
shaved using electric shears followed by application of a depilatory cream (Nair). Patches 
were applied to the hairless skin section and left for 20 minutes.  Additional hair removal 
using shears and depilatory cream was done prior to boost. No evidence of scabbing due 
to depilatory cream application was seen.  
Visual evidence of skin punctures by microneedle arrays was noticeable (to a 
trained eye) immediately after administration; in a few cases, trace blood residue was 
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observed on the sites of a few MNs on used patches. Blood was collected weekly and 
analyzed for antibodies, The protocol for these experiments was approved by the 
IACUCs at CDC and Georgia Tech. 
To confirm the dose delivered to the skin of the macaques, residual HBsAg in the 
patches used for the second dose was measured post-administration and subtracted from 
the original antigen loading. Based on these data, delivery efficiency (the ratio of 
delivered antigen to loaded antigen) was determined to be  63 ± 16 %.  
3.7   Statistics  
Statistics were performed using Prism software version 7 (GraphPad, La Jolla, CA). P 
values < 0.05 were considered significant. A two-way ANOVA with a Tukey post-test 




CHAPTER 4.   RESULTS 
4.1   Mechanical Characterization 
Stainless steel MNs have been shown to have sufficient mechanical strength to 
penetrate into skin40,60–62 and therefore have not been mechanically characterized here. 
However, dissolvable MNs are typically not as strong and their design is strongly 
influenced by mechanical strength considerations. Therefore, the mechanical behavior of 
dissolvable microneedle patches were characterized to relate the failure of these 
microneedles as determined by force-displacement curves analyzed in the context of 
beam theory. 
4.1.1   Measurement of Microneedle Failure 
Mechanical behavior of microneedle patches was studied by generating force-
displacement curves obtained by pressing patches containing a 10 by 10 array of 
dissolvable microneedles against a rigid surface. In general, force increased with 
increasing applied displacement, but the response could be divided into two regions 
(Figure 6). Based on 11 replicate measurements, we found that at small displacement 
(i.e., less than 0.15 ± 0.05 mm) there was a roughly linear increase in force that led to an 
apparent yield point at 1.1 ± 0.6 N of axial force applied to 100 microneedles (i.e., 11 ± 6 
mN per microneedle).  
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Figure 6: Representative force-displacement curve for a 10x10 microneedle patch. 
Data shown is for a single dMNP.   
 
Microneeedles were imaged following application of different axial forces. 
Unused microneedles showed a continuously tapered conical structure and a sharp tip 
(Figure 7a). After application of 5 N (above the transition from the first to second 
region), initial evidence of microneedle tip deformation could be seen (Figure 7b). 
However, at higher forces of 15, 25, 50 and 75 N (Figures 7c,g,h,i), progressively greater 
microneedle tip deformation was seen. Under the conditions used, microneedle fracture 




 Figure 7: Microneedle deformation (from left to right: 0, 5, 15, 25, 50 and 75 N 
of applied force) and subsequent insertion into ex-vivo pig skin site of patch 
application shown in box. Scale Bar (a-c, g-i): 500 µm. Scale bar (d-f, j-l): 1mm 
Comparing the forces associated with changes in measured mechanical properties 
(Figure 6) and with morphological changes observed microscopically (Figure 7), it 
appears that the mechanics in Region I of the force-displacement curve correspond to the 
behavior of intact microneedles and the yield point which corresponds to the point of 
initial deformation of the microneedles (occurring between Figures  7a and 7b). Region II 
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appears to correspond to progressively increasing microneedle tip deformation (occurring 
between Figures 7b and 7c) and, at higher forces microneedle tips appear crushed and the 
matrix material begins to fan out in a radial direction (Figures 7g-i),. 
While microneedle tip deformation is not good for insertion into skin, it may be that 
some deformation is acceptable. We therefore assessed the ability of microneedles to 
penetrate into skin after different levels of tip deformation. Intact microneedles were able 
to penetrate the skin efficiently, as indicated by an assay that stains sites of microneedle 
penetration into skin (Figures 7d-f, j-l). At 5 N, there was minimal damage to the tips and 
insertion efficiency remained high (Figure 7e). At 15 N, minor chipping and hooking of 
the tip occurred. However, subsequent insertion of the microneedle array into skin was 
only slightly reduced compared to that of an intact patch (Figure 7f). At 25 N and 50 N, 
there was increased bending and tip deformation that correlated with a loss of insertion 
efficiency, as evidenced by the reduction of penetration holes (Figure 7j-k). Finally, at 75 
N, microneedle tips were crushed and no longer able to penetrate skin (Figure 7l). These 
data are quantified in Figure 8a.  
The reduction of microneedle height was measured by comparing microscopic 
images of stressed microneedles to intact microneedles (e.g., Figure 7a-c,g-i). With 
increasing force, there were greater reductions of microneedle height initially but then 
microneedle height plateaued at a value of approximately 50% height loss (residual 
height approximately 300 µm) (Figure 8b). The increase in microneedle tip diameter that 
accompanies loss of height results in a blunt tip which could hinder insertion, though 
crushed tips with up to 200 µm height loss (i.e., patches compressed with up to 15 N) still  




Figure 8: (a) Insertion efficiency for applied forces to a dissolving microneedle. 
Total applied force was divided by the amount of microneedles in a 10x10 array. (b) 
Estimated microneedle height loss. 
 
4.1.2   Theoretical Calculations of Microneedle Failure Force 
To better understand the observed microneedle mechanics, we sought to model 
the microneedle behavior. Critical force loads were of primary interest, so we modeled 
them using the Euler formula for buckling. We felt the Euler formula was most 
appropriate to model microneedles under compression during application to a rigid 
surface (i.e., what we did in our experiments) based on a comparison between our 
needle’s column constant and slenderness ratio, as described in Park, et. al51 (see 
Appendix A). 
 
a                                             b  
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Table 1: Predicted critical force values for a 10x10 microneedle patch according to 
Euler’s Formula. 
 





Using the Euler formula, we evaluated critical force loads for three possible scenarios: 
fixed-fixed, pinned-pinned and fixed-pinned end (see Appendix A). Estimates from 
Euler’s formula calculation range from 0.5-2.0 N (Table 1). This is in good agreement 
with the failure force of 1.1 ± 0.6 N observed experimentally. Since there is no rotation 
occurring at either end of the microneedle, we consider fixed-fixed to be the more 
appropriate scenario to use for future estimations of microneedle failure force. 
Ultimately, although microneedles have a varying diameter, the mechanical behavior of 
our microneedle patches can be studied by using the Euler formula, which treats 
individual microneedles as columns. 
4.2   Immunogenicity in Mice  
As a first assessment of the immunogenicity of HBsAg administered using 
microneedle patches, we evaluated immune response to vaccination with coated 
microneedle patches as well as dissolvable microneedle patches to administer two doses 
HBsAg (separated by three weeks) to mice. The study included five groups. Two groups 
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were vaccinated using coated or dissolvable microneedle patches, and three groups were 
vaccinated intramuscularly. One of the intramuscular groups administered vaccine as 
received from the manufacturer. The other two groups received vaccine reconstituted 
from coated or dissolvable microneedle patches. The reason for including these last two 
groups was to determine if anything associated with the microneedle patch manufacturing 
process affected vaccine immunogenicity (independent of the microneedle patch route of 
administration to the skin).  
We characterized the immune response in terms of seroprotection (i.e., anti-HBs > 
12 mIU/mL)63 (Figure 9). Two weeks after administration of the first vaccine dose, 38% 
of mice in the dissolving microneedle patch group achieved seroprotection, but none of 




Figure 9: Seroprotection for dissolvable microneedle (dMNP), unadjuvanted bulk 
antigen (IM) and reconstituted dissolvable microneedle patches (IM (dMNP)) 
groups. Animals were vaccinated at week 0 and again at week 3.  
One week after the second vaccination (i.e., four weeks into the study), all groups 
had at least 50% seroprotection, except the coated microneedle patch group that had only 
25% seroprotected animals. At the end of the study after 8 weeks (i.e., five weeks after 
the second vaccine dose), all groups had at least 50% seropositive animals (although 
animals that received the reconstituted dissolvable microneedle patch had only 50% 
seroprotection). Overall, we can conclude that HBsAg vaccine administered by coated or 
dissolvable microneedle patches is immunogenic in mice.  
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Considering safety, no adverse events were noted in any of the animals. At the site 
of vaccination, the microneedle patches were well tolerated, with no bleeding or 
erythema observed; in contrast a small drop of blood was sometimes seen at the sites of 
hypodermic injection.  
4.3   Immunogenicity in Macaques 
Guided by the immunogenicity results in mice, we vaccinated rhesus macaques 
with two doses of HBsAg vaccine (separated by nine weeks) as either adjuvanted 
(commercial formulation provided by Serum Institute of India) or unadjuvanted vaccine 
via intramuscular injection or unadjuvanted vaccine by dissolvable microneedle patch. 
Blood draws at weeks -1 and -2 confirmed no initial presence of anti-HBs antibodies 
(anti-HBs < 1 mIU/mL). 
Local reactions to microneedle patch vaccination were mild (Figure 10). 
Immediately after removing the patch, there was faint evidence of the site where the 
microneedles had penetrated the skin (square shape in Figure 10b) and where the 
adhesive had contacted the skin (round shape in Figure 10b) during patch application.  
No erythema or other signs of irritation was observed. In about 10% of the patches, a 
speck of blood was seen on the residual patch post-administration. Macaque weights 
were monitored during the study, and only one macaque showed significant (13%) body 
weight loss during the course of the study (this animal was in the dMNP group). No other 




Figure 10: Microneedle patch application on rhesus macaque.  Patches were applied 
to shaved back skin and left on for 20 minutes. Images show a) patch in place b) 
macaque skin immediately after patch removal.  
 After administration of the first vaccine dose, all groups showed at least partial 
seroprotection: 100% in the adjuvanted intramuscular group, 75% in the microneedle 
patch group and 50% in the nonadjuvanted intramuscular group (Figure 11). After the 
second dose, macaques vaccinated intramuscularly with the commercial adjuvanted 
formulation continued to maintain 100% seroprotection until the end of the study. 
Animals receiving the unadjuvanted vaccine intramuscularly achieved 100% 
seroprotection the week after the second dose (week 10) and then dropped to 75% 
seropositive by week 17. The (unadjuvanted) microneedle group achieved 100% 




Figure 11: Seroprotection for bulk antigen (IM), adjuvanted antigen formulation 
(IM-adj) and dissolvable microneedle patch (dMNP) macaque groups. 
 
Figure 12: Mean anti-HBc antibody for macaques. Arrows indicate vaccine 
administration times. Results are shown as mean +/- SD (n=4 for all groups until 
week 8. dMNP group was n=3 for weeks > 8, due to non-study-related loss of an 
animal). Dotted line indicates threshold for seroprotection. 
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 The immune response can be further examined by looking at the anti-HBs IgG 
titers after vaccination (Figure 12). Immediately after the first vaccination (weeks 1 and 
2), there was no significant difference in the average antibody titers among the three 
groups (P > 0.05). After that, the titers in all groups roughly maintained their values, and 
microneedle patch group response by week 8 was not significantly different from the 
intramuscular groups (P > 0.05).  
After the second vaccine dose, the microneedle patch and unadjuvanted 
intramuscular vaccine groups generated almost identical responses with initially 
increased titers that slowly decayed over time. The adjuvanted intramuscular vaccine led 
to a significantly greater increase in titers after the second vaccination dose (P  < 0.0001), 
but also decayed in value over time. Overall, this study shows that HBsAg vaccination 
using a microneedle patch is immunogenic in a nonhuman primate model (rhesus 
macaque).  
While we only discussed one microneedle patch group in the above analysis, there 
were actually two microneedle patch groups in the study: one received a lower dose, 
which was already presented, and the other received twice the dose, which has not yet 
been discussed. The high-dose group presented anomalous behavior, with two monkeys 
that responded to vaccination with only low titers and the other two monkeys were 
complete non-responders to microneedle patch vaccination, even after two doses. 
Furthermore, after completion of our study, the non-responsive macaques were 
vaccinated with the commercial adjuvanted formulation intramuscularly and only then 
was seroprotection obtained (data not shown). We are not able to distinguish whether the 
animals had been primed by the microneedle patches or whether this was a primary 
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response to IM vaccination. These strange data (i.e., much weaker responses compared to 
the low-dose microneedle patch and both intramuscular groups) may be related to patch 
function or variability within the small sample size of outbred animals.  
For that reason, we present the data including this group in Appendix B, but refrain 














CHAPTER 5.   DISCUSSION 
5.1   Mechanical Characterization of Microneedles 
Effective microneedle insertion into skin relies on parameters like needle 
geometry, needle aspect ratio and array size. Microneedle patch design must take into 
account these factors as well as others like microneedle density, as this can lead to issues 
like the “bed of nails” effect where a tightly packed array acts as a single entity causing 
improper skin deflection. In the case of dissolvable microneedles, it is even more crucial 
to ensure array design facilitates insertion. By using an entire microneedle array during 
force testing - as opposed to a single microneedle - we hope to capture the behavior most 
relevant for the insertion process for needles of this geometry.  
Previous works have explored the effect of different base geometries64, as well as 
aspect ratio of microneedles.51 Previous work has determined the failure force of 3 x 3 
conical microneedle arrays made out of CMC.24  Here, we sought to characterize the 
mechanical properties of a 10 x 10 dissolvable microneedle patch with conical 
microneedles having a height of 600 µm. In addition, the loss of microneedle volume due 
to crushing was characterized in order to demonstrate the force that can be applied 
without a significant loss of insertion efficiency.  
A brittle failure point was never observed under compression for the 10 x 10 
dMNPs under the conditions studied. It is certainly possible that under non-axial force 
loading situations the microneedle patch could experience sudden brittle failure or even a 
plateauing indicating ductile failure. However, it ultimately is clear from the force-
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displacement curves as well as from imaged patches that the microneedles in this study 
fail through yielding. It is well documented that residual water content in polymers acts 
as a plasticizer, and therefore it is likely that the observed behavior is a function of 
residual moisture in the microneedle patch.   
The data obtained through force-displacement curves suggest that the current 
microneedle patch design starts to fail at 11 ± 6 mN per microneedle. It has been shown 
by others that conical polyvinylpyrrolidone (PVP) microneedles and CMC microneedles 
(15 x 15 and 3 x 3 arrays, respectively) had failure forces at ~100 mN/needle.29,65 Given 
the different materials and microneedle patch design, we do only expect rough agreement 
with these studies. Furthermore, a study by Park et. al found that conical poly(lactic-co-
glycolic acid) (PLGA) microneedles failed at around 175 µm of compression for MNs 
with a height of 570 µm. These findings are comparable to our observation that our 
microneedles with a height of 600 µm failed at 170 ± 70 µm of compression. Despite 
these reported failure forces, it is of interest to note that insertion into skin was still 
possible in this study at forces three times higher than the observed force for failure, 
meaning that this failure force is not the maximum force that a microneedle can tolerate 
before being made useless for insertion into skin, but that larger forces can be tolerated 
while still permitting microneedle penetration into skin. 
Microneedle patches were kept in a sealed, dark pouch with desiccant until use in 
this study. The failure force exhibited by the dMNPs varied by 50% (i.e., 11 ± 6 mN per 
microneedle at yield point), and this may have been affected by the length of time the 
microneedle patches were kept in storage before use. It is possible that variability in 
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failure force was due to insufficiently controlled microneedle water content due to 
humidity changes over time after removal from the desiccated storage pouch. 
5.2   Immune Response to HBsAg Vaccination using Microneedle Patches 
The main goal of this study was to assess the immunogenicity of dissolving 
microneedle patches containing HBV vaccine in both mice and rhesus macaques. We 
showed via in vivo studies that skin vaccination using our current formulation for 
dissolvable microneedle patches elicited a fast and sustained immune response that was 
comparable to the current intramuscular vaccine. Notably, in our mouse study, protective 
immune response started developing two weeks faster than via intramuscular 
administration.  
Interestingly, in our macaque study half of our high-dose group was non-
responsive, and the other half had titers that although seroprotective, were much lower 
than those of the low-dose microneedle group. It remains unclear why this occurred, as 
patches were shown to be antigenic in vitro. Nonetheless, 6 out of 8 macaques that 
received patch vaccine generated anti-HBs antibodies. Overall, this work shows that 
microneedle patches can successfully deliver hepatitis B antigen to generate a strong and 
sustained immune response in more than one animal model. 
5.3   Potential Impact on Public Health 
Vaccination against HBV is the principal way to address and control the long-term health 
and economical burdens associated with this disease. Although in 1991 the World Health 
Organization recommended a universal hepatitis B vaccination policy to be effective by 
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1997, its implementation was hampered for many years by the high cost of HBV vaccine 
compared to other Expanded Program on Immunizations (EPI) vaccines.8 With funding 
from sources like GAVI, the addition of HBV vaccine as part of the routine infant 
immunization schedule and dramatically cheaper vaccine offered by developing country 
vaccine manufacturers have boosted coverage significantly, efforts are needed to address 
populations not currently benefitting from current public health policy7. Currently, the 
countries with least HBV vaccination coverage suffer from disadvantaged economies 8 
and limited health-care infrastructure. The possibility of an inexpensive, easy to distribute 
vaccine holds great potential to overcome the financial and logistical hurdles associated 
with vaccination campaigns. 
 The current design for dissolvable microneedle patches has been shown to allow 
for administration without the use of an applicator or advanced training.22 Because of the 
CDC recommendation that first administration occur at birth, this mode of vaccination 
could be of particular benefit in cases where cultural preference or lack of resources 
result in a non-hospital birth. A microneedle patch would facilitate vaccination in these 
cases without the need for additional medical intervention. Finally, microneedle patches 
are lightweight, and could cut down on the wastage produced with the current multi-dose 
vials. Further development of this technology would open up the possibility to distribute 
and administer in remote locations, and optimize the efforts of health workers spread thin 




In this work, we developed dissolvable microneedle patches that administer HBV 
vaccine (HBsAg) and evaluated their immunogenicity in BALB/c mice as well as rhesus 
macaques. These vaccine patches were found to be immunogenic, and 75% 
seroprotection was achieved for the rhesus macaque model. Moreover, the data shown in 
this work suggests that dissolving microneedle patches fail by yielding as opposed to 
brittle fracture, but also that limited minor microneedle tip deformation may not have a 
significant effect on insertion. Ultimately, microneedle patches present many logistical 
advantages for improving vaccination coverage worldwide, by offering an easy 
alternative for infant vaccination that can be used in births that occur in remote, non-




These studies confirmed that HBV vaccine could be encapsulated within a dissolving 
microneedle patch to elicit a robust immune response in two different pre-clinical animal 
models. Future work should center on improving vaccine stability, with consideration to 
different temperature and humidity conditions. This can be achieved by performing an 
expansive screening of excipients. It is of importance to find long-term thermostability 
because it would be a substantial benefit to make this kind of technology more 
economical to implement at a large scale.  
Another focus of future work should be the evaluation of the possibility of dose 
sparing even without adjuvantation. Additional research can assess this by additional in 
vivo studies that further optimize vaccine stability and delivery from the microneedle 









APPENDIX A. THEORETICAL CALCULATIONS FOR 
CRITICAL FORCE 
The slenderness ratio of a column is calculated by: 





SR values for our microneedles were 26.7, 18.7 and 13.3 using K values of 1.0, 0.7 and 
0.5, respectively (see sample calculation below). 
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 To confirm that Euler’s formula applied to our geometry, the column constant 
was calculated and compared to our slenderness ratio values. The column constant 
provides a transition point to determine whether the column is considered “short” or 
“long” (and therefore whether Euler’s formula applies) 




For all K values studied, the slenderness ratio is larger than the column constant, and so 














(𝐷56) 90 µm 
E 5.69 x 109 Pa 
K 0.5,0.7 or 1.0 n/a 
microneedle 
height (L) 6.00 x 10-6 m 
critical load 
(Fcr)  N 
To determine the critical load for each scenario, the corresponding effective length (Le) is 
obtained by multiplying microneedle height (L) and K. Critical load is determined by 





Where the moment of inertia is calculated using the following equation: 
𝐼 =
𝜋𝐷56.
















Figure B1: Seroprotection for bulk antigen (IM) and adjuvanted antigen 
formulation (IM-adj) and low and high dose dissolving microneedles (dMNP and 











Figure B2: Mean anti-HBc antibody for macaques. Arrows indicate vaccine 
administration. Data includes low and non-responders in the MN-high group. 
Results are shown as mean +/- SD (n=4 for all groups until week 8. dMNP group 
was n=3 for weeks > 8). Dotted line indicates threshold for seroprotection. 
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